The AEROTOXIC SYNDROME Professor Michael Bagshaw United Kingdom

Similar documents
Health Effects of Contaminants in Aircraft Cabin Air

BASIC PHYSICS APPLIED TO ANAESTHESIOLOGY

I Physical Principles of Gas Exchange

Lung Volumes and Capacities

Essential Skills Course Acute Care Module. Respiratory Day 2 (Arterial Blood Gases) Pre course Workbook

RESPIRATORY REGULATION DURING EXERCISE

Chapter 17 The Respiratory System: Gas Exchange and Regulation of Breathing

2 Hazards identification

Respiratory Lecture Test Questions Set 3

Applied Physics Topics 2

: Red Caries Indicator

By: Aseel Jamil Al-twaijer. Lec : physical principles of gas exchange

A survey of health effects in aircrew exposed to airborne contaminants

Respiratory physiology II.

MSDS ENGINE RESTORER & LUBRICANT WITH CSL 19/11/09 p. 1 of IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING :

SAFETY DATA SHEET Revised edition no : 6

Section Two Diffusion of gases

PICU Resident Self-Study Tutorial The Basic Physics of Oxygen Transport. I was told that there would be no math!

Respiration. Figure 22: Schematic representation of the respiratory system

Unit II Problem 4 Physiology: Diffusion of Gases and Pulmonary Circulation

SAFETY DATA SHEET 49N SYNTHETIC GLOBAL ATF Revision Date:

: Mitomic Prostate Test Real-Time PCR Kit

POLICY FOR THE CONTROL OF SUBSTANCES HAZARDOUS TO HEALTH (COSHH)

The Physiologic Basis of DLCO testing. Brian Graham Division of Respirology, Critical Care and Sleep Medicine University of Saskatchewan

Respiratory System. Part 2

Micador Rubber Cement

SAFETY DATA SHEET. Product: Catnip Oil EOS121. Section 1. Identification of the substance or the mixture and of the supplier

SAFETY DATA SHEET PEELAWAY 7 Page: 1 Compilation date: 14/04/2015 Revision date: 9/11/2017 Revision No: 2

respiratory cycle. point in the volumes: 500 milliliters. for men. expiration, up to 1200 milliliters extra makes breathing Respiratory

Gases and Respiration. Respiration Overview I

SECTION 1: Identification of the substance/mixture and of the company/undertaking

SAFETY DATA SHEET GREASE MOLYBDENUM

SAFETY DATA SHEET. Restrictions on use : Reserved for industrial and professional use. : ,

TALBOT MARKING/LAYOUT FLUID SAFETY DATA SHEET

Gas exchange. Tissue cells CO2 CO 2 O 2. Pulmonary capillary. Tissue capillaries

Physical Chemistry of Gases: Gas Exchange Linda Costanzo, Ph.D.

Krytox NRT 8908 Paste

BRAKE FLUID - DOT 4 MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET

Revision Date 26-Sep IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING. No information available

Respiratory Physiology. Adeyomoye O.I

Carpet, upholstery and fabric spot stain remover. (see Approved Criteria for Classifying Hazardous Substances (NOHSC: ))

: KLEENEX Luxury Foam Non-Alcohol Instant Hand Sanitiser

SAFETY DATA SHEET CARLUBE 5W30 LONGLIFE

IATA Guidance for airline health and safety staff on the medical response to Cabin Air Quality Events

UNIQUE CHARACTERISTICS OF THE PULMONARY CIRCULATION THE PULMONARY CIRCULATION MUST, AT ALL TIMES, ACCEPT THE ENTIRE CARDIAC OUTPUT

RESPIRATORY GAS EXCHANGE

Safety Data Sheet. SECTION 1: Identification of the substance/mixture and of the company/undertaking. SECTION 2: Hazards identification

SUMMARY OF PRODUCT CHARACTERISTICS. 1 NAME OF THE MEDICINAL PRODUCT Lung test gas, CO/He AGA 0.28%, 9.3% medicinal gas, compressed

SAFETY DATA SHEET CARLUBE CHAINSAW OIL

SAFETY DATA SHEET 20W/50 MOTOR OIL

Safety Data Sheet. (Magnesium Aspartate 20%) DATE PREPARED: 6/15/2015. Section 1. Product and Company Identification

Noxious Fumes and Gases

Date Printed: 03/13/2008 Date Updated: 01/29/2006 Version 1.3. Product Name BROMOPENTACARBONYLMANGANESE(I), 98% Product Number

Revision Date 13-Jul IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING. No information available

SAFETY DATA SHEET. Section 1: Identification of the substance/mixture and of the company/undertaking. Section 2: Hazards identification

Safety data sheet Label elements The product shall not be classified as hazardous according to EU classification and labelling rules.

SAFETY DATA SHEET according to Regulation (EU) 2015/830

SAFETY DATA SHEET Pneumatic tool oil Luna AIRTOIL , 0205, 0304


The Following information is based on material prepared by the American Lung Association


MATERIAL SAFETY DATA SHEET

Section Three Gas transport

S A F E T Y D A T A S H E E T

Table of Contents. By Adam Hollingworth

Emergency Overview HARMFUL OR FATAL IF SWALLOWED. COMBUSTIBLE. EYE AND SKIN IRRITANT.

SAFETY DATA SHEET DEXRON III TRANSMISSION FLUID

Material Safety Data Sheet WPF

SAFETY DATA SHEET. Identification of the material and the supplier. Wiri Auckland. Composition / Information on Ingredients

EXP-NBD103 Native Barcoding Kit 1D

Public Assessment Report Scientific discussion. Lung test gas CO (He) AGA, 0.28%, inhalation gas, compressed (carbon monoxide, helium) SE/H/1154/01/MR

WEBINARS. Hazard Communication

SDS. Safety Data Sheet According to Regulation (EC) No. 1907/2006. : CLAC Electrolyte Solution

X BOND CONSTRUCTION ADHESIVE SEALANT

SAFETY DATA SHEET SURESHOT FRUIT & VEGETABLE TREATMENT

SAFETY DATA SHEET FOR PATINATION OIL

SAFETY DATA SHEET BUMPER AND TRIM GEL

SMOKE & FUME / SMELL EVENTS

: MR MUSCLE Shower Shine

SAFETY DATA SHEET. AccuStandard, Inc SECTION 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION Product Identifiers

Revision Date 13-Jul IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING. Cyproheptadine hydrochloride

Safety data sheet. according to 1907/2006/EC, Article 31. SECTION 1: Identification of the substance/mixture and of the company/undertaking

Relevant identified uses of the substance or mixture and uses advised against

Safety Data Sheet according to (EC) No 1907/2006

Page 1 / 7 Safety Data Sheet according to the Global Harmonised System. Cleaning Fluid. Issuing Date Revision Date Version 1

SAFETY DATA SHEET DEXRON II

CHAPTER 3: The respiratory system

SAFETY DATA SHEET. In accordance with REACH Regulation EC No.1907/2006 SECTION 1. IDENTIFICATION OF THE SUBSTANCE OR THE MIXTURE AND OF THE SUPPLIER

660 mm Hg (normal, 100 mm Hg, room air) Paco, (arterial Pc02) 36 mm Hg (normal, 40 mm Hg) % saturation 50% (normal, 95%-100%)

Safety Data Sheet MasterLife SF 100 also RHEOMAC SF 100 Revision date : 2012/10/29 Page: 1/6

SAFETY DATA SHEET WINDOW AND SPRAY AND WIPE

Safety data sheet according to 1907/2006/EC, Article 31

PDF created with pdffactory Pro trial version SAFETY DATA SHEET

Safety Data Sheet. SECTION 1: Identification. SECTION 2: Hazard identification

SAFETY DATA SHEET According to Safe Work Australia

SAFETY DATA SHEET. In accordance with REACH Regulation EC No.1907/2006. Section 1. Identification of the substance or the mixture and of the supplier

Safety data sheet according to 1907/2006/EC, Article 31

: Acoustic Topcoat Plaster

SAFETY DATA SHEET. Paraffin Liquid. Address: 1809 Lytton Road, Lytton, Queensland Phone: (07) Fax: (07)

Transcription:

The AEROTOXIC SYNDROME Professor Michael Bagshaw United Kingdom Concerns have been raised by unions representing pilots and cabin crew about the possible effects on aircrew health of oil/hydraulic fluid smoke/fume contamination incidents in pressurised aircraft. Specific concerns have been raised with respect to organophosphate compounds (OPs) in the cabin air environment and the effects on health of long term low-level exposure. However, the epidemiological evidence is hampered by inconsistency in reporting and the numbers are small. Organophosphates in Engine Oil Mobil Jet Oil II is commonly used for jet engines. This contains synthetic hydrocarbons and additives, including the organophosphate Tricresyl Phosphate (TCP) which acts as a high pressure lubricant. Engine lubricating oil contains around 3% TCP. TCP is a toxic mixture that can cause a wide array of transitory or permanent neurological dysfunction when swallowed. The toxic effect of the ortho isomer, TOCP, is impairment of neuromuscular and peripheral nerve synapse function; it has no toxic effect on brain or cognitive function. The para and meta isomers are not toxic to humans. There have been no independently peer-reviewed recorded cases of neurological harm in humans following dermal or inhalation exposure to TCP. An unpublished report from the Medical Toxicology Unit at Guy s Hospital in 2001 stated that the majority of cases of tricresyl phosphate poisoning have been associated with the swallowing of contaminated food or drink, not with occupational exposure. The most frequent occupational exposures occur during manufacture, packaging, shipping and storage, not at the point of product use, and reports of occupational intoxication are rare. The report quotes documented exposures dating back as far as 1943 and all the

exposures are to high concentrations greatly in excess of the amount present in jet oil. A Canadian study in 1998 was unable to detect TCP in-flight and another study in the USA also failed to detect TCP during in-flight measurements. British Airways commissioned a study by an independent specialist on indoor air quality, BRE, in 2001. BRE found that the concentrations of all oil compounds detected in cabin air were well below the human toxicological threshold. In 2004 the UK government Aviation Health Working Group commissioned BRE to analyse a wide range air quality parameters during different phases of flight, including tests for oil vapours. This supplemented an earlier 2001-2003 EU-funded research project, CabinAir, which monitored air quality on 50 European airline flights. Both surveys concluded that no air pollutant exceeded recommended health limits; hardly any trace of oil vapour was detected. A similar finding was reached by another EU-funded project, Health Effects in Aircraft Cabin Environment (HEACE), in 2001-2005. Because of continuing concerns the UK Department for Transport (DfT) commissioned the Committee on Toxicity of Chemicals in Food Consumer Products and the Environment (COT) to undertake an independent scientific review of available data in 2007. Summary of COT review on cabin environment and aircrew health. There was considerable uncertainty about the identity of volatile organic compounds (VOCs) and other pyrolysis products released into the cabin air during a smoke/fume event. Further specific monitoring was recommended. There was insufficient evidence to recommend additional epidemiological research on any acute health effects. The evidence available allowed no conclusion to be reached that there is a causal association between cabin air exposures and ill health in commercial aircraft crew members. However, an association remains plausible. Following the COT review, the DfT has commissioned further in-flight studies. HUMAN TOXICOLOGY The human body has its own defence mechanisms which protect against harm from certain levels of hazardous substances. However, if these levels are exceeded it is possible for health to be affected, either immediately (acute effects) or some time after the first exposure (chronic or delayed effects). Individuals can vary in their response to toxic insult because of age, health status, previous exposure or genetic differences. Some individuals are more

susceptible to adverse effects when exposed to certain chemicals; the genetic basis for differences in susceptibility is being increasingly understood. It can also be difficult to disentangle the physical, psychological and emotional components of well-being, and there is no doubt that different people may respond in different ways on different occasions. The human senses, particularly the sense of smell, are generally very effective in detecting hazardous substances at a level well below that which causes harm (except carbon monoxide). The fact that a potentially hazardous substance can be smelt does not imply that it is of sufficient concentration to cause harm. For most volatile organic compounds, the concentration level for detection by a normal healthy human is around 1,000 times less than the concentration level which is likely to harm health. Absorption and Distribution of Chemicals Foreign or exogenous chemicals (xenobiotics) must be absorbed from the surrounding environment and transported to their target site in the body for a toxic effect to occur. The chemical has to cross many cell membranes which form a lipoprotein barrier to the outside as well as maintaining the integrity of the cell. Most xenobiotics are transported by simple methods and not complex carrier-associated processes. Lipid solubility is one of the major factors determining the extent and rate of simple diffusion through a lipoprotein membrane. Lipophilic molecules diffuse more readily than those which are hydrophilic, the rate of transport being dependent on the partition coefficient (ie the ratio of solubility in octanol/water). Non-ionised molecules are often more lipophilic and ions generally more hydrophilic, so the movement of electrolytes, such as organic acids and bases, is related to the degree of ionic dissociation and the lipid solubility of the non-ionised form of the compound. The cell membrane controls the movement of chemicals in or out of the cytoplasm. Inhalation Kinetics The lung tissue barrier (alveolar membrane) separating air and blood is only 0.5-1.0 μ thick and the 300-400 million alveoli provide a large surface area for diffusion. In accordance with Fick s law, the transfer of gases through the alveolar membrane depends on the area and thickness of the membrane, and the partial pressures of the gases in the blood and in the alveoli. The media on either side of the alveolar membrane are being continuously renewed; the air is changed 12-15 times per minute and the pulmonary blood flows at 3.5-5 litre per minute at rest, at sea level. This leads to efficient absorption, and elimination, of volatile chemicals. Factors influencing the inhalation kinetics of a volatile compound include the environmental air concentration, duration of exposure, rate of alveolar ventilation, cardiac output, blood and tissue solubility and the degree of metabolism of the chemical. Volatile compounds are usually inhaled as a gas mixture with air and most are completely miscible in all proportions. The

concentration of gases and volatile compounds in a mixture is expressed in terms of partial pressure, which is not equivalent to concentration. However, the relative concentrations of dissolved materials can be expressed in terms of partial pressures which add up to a total pressure of 100%. Solubility is inversely related to the temperature and proportional to the pressure of the chemical in the ambient gas. The partial pressures of constituent volatile compounds vary with the absolute pressure but, at a fixed pressure, the concentration of each gas or vapour varies directly with its partial pressure and indirectly with the total pressures of the gas/vapour mixture. The rate of delivery of an inhaled mixture of air and a volatile compound depends upon alveolar ventilation. A doubling of alveolar ventilation from 4 to 8 litre/min produces a minimal increase in the blood concentration of a poorly water soluble substance but an appreciable increase for highly water soluble substances. Cardiac output has an opposing effect on alveolar concentration and this is most noticeable for highly water soluble or extensively metabolised substances rather than poorly soluble compounds. An increase in cardiac output results in a larger amount of the inhaled substance passing from the lungs to the blood. A decrease has the opposite effect and causes a rise in alveolar concentration. AEROTOXIC SYNDROME A syndrome is defined as a set of symptoms which occur together, or the sum of signs of any morbid state, or a symptom complex. It follows that there should be a consistent set of common symptoms which together make up a given condition. Individuals reporting that they suffer from the so-called aerotoxic syndrome describe a wide range of individual symptoms and signs, with insufficient consistency to fulfil the requirements for the definition of a medical syndrome. Many of the reported acute symptoms are largely the same as those reported by participants in all phase 1 drug trials, being normal symptoms experienced by most people on frequent occasions. It is recognised that 70% of the population experience one or more of them on any given day. Both the US National Academy of Science and the Aerospace Medical Association reviewed the scientific evidence and concluded that there was insufficient consistency and objectivity to support the establishment of a clearly defined syndrome. Thus the concept of the Aerotoxic Syndrome is not recognised in the aviation medicine community. Symptoms reported by some crew members who have been exposed to fumes in the cabin are similar to those seen in a wide range of conditions, including chronic fatigue syndrome, Gulf War syndrome, Lyme disease, chronic stress and chronic hyperventilation. The UK has approximately 20,000 professional pilots. In 2008, the UK CAA Medical Department database has 21 pilots reporting symptoms connected with this issue. Of these, 10 are long-term unfit, 2 are temporarily unfit, 6 are fit and 3 have allowed their medical certificates to expire.

CONCLUSION There has been an increase in reported incidents of in-flight smoke/fume events since 1999, with a small number of crew members reporting adverse health effects which they associate with the events. The source of oil contamination of engine bleed air was identified in early versions of the BAe 146 and the Boeing 757 and suitable modifications were implemented. A range of chronic health effects are reported by some crew members, although there have been no payments of damages to affected individuals. The reported symptoms are wide-ranging with insufficient consistency to justify the establishment of a medical syndrome. It has been noted that many of the acute symptoms are normal symptoms experienced by most people frequently; some 70% of the population experience one or more of them on any given day. Individuals can vary in their response to toxic insult because of age, health status, previous exposure or genetic differences. In addition, it can be difficult to disentangle the physical, psychological and emotional components of well-being, and there is no doubt that different people may respond in different ways on different occasions. Symptoms reported by some crew members who have been exposed to fumes in the cabin are similar to those seen in chronic hyperventilation. September 2008